FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO): study protocol for a randomised, multicentre, phase IIa, placebo-controlled trial.

ABSTRACT:

Introduction

Primary sclerosing cholangitis (PSC) is the classical hepatobiliary manifestation of inflammatory bowel disease (IBD). The strong association between gut and liver inflammation has driven several pathogenic hypotheses to which the intestinal microbiome is proposed to contribute. Pilot studies of faecal microbiota transplantation (FMT) in PSC and IBD are demonstrated to be safe and associated with increased gut bacterial diversity. However, the longevity of such changes and the impact on markers of disease activity and disease progression have not been studied. The aim of this clinical trial is to determine the effects of repeated FMT as a treatment for PSC-IBD.

Methods and analysis

FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO) is a

SUBMITTER: Al-Shakhshir S 

PROVIDER: S-EPMC11749870 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature